Phase I clinical and gene modulatory evaluation of tamoxifen and IFN-α2b

Journal of Interferon and Cytokine Research

Volumn 26, Issue 11, 2006, Pages 800-803

  Thakkar, Snehal G ^a   Peereboom, David ^a   Olencki, Thomas ^b   Jacobs, Barbara ^a   Elson, Paul ^a   Rybicki, Lisa ^a   Lindner, Daniel J ^a   Borden, Ernest C ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; ESTROGEN RECEPTOR; GENE PRODUCT; NEOPTERIN; PROTEIN INTERFERON STIMULATED GENE 15; RECOMBINANT ALPHA2B INTERFERON; TAMOXIFEN; UNCLASSIFIED DRUG; ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR PROTEIN;

ADULT; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ARTICLE; ATAXIA; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DEATH; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG TOLERANCE; DYSPNEA; FEMALE; FEVER; GENE; GENE EXPRESSION; GRANULOCYTOPENIA; HUMAN; INTERFERON STIMULATED GENE; KIDNEY CARCINOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; MOOD CHANGE; NAUSEA; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TITRIMETRY; TRANSCRIPTION REGULATION; VISUAL IMPAIRMENT; VOMITING; ANIMAL; BIOSYNTHESIS; DOSE RESPONSE; DRUG EFFECT; EVALUATION; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; MORTALITY; MOUSE; NEOPLASM;

MURINAE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EVALUATION STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON ALFA-2B; MALE; MICE; NEOPLASM PROTEINS; NEOPLASMS; TAMOXIFEN;

EID: 33751116549     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2006.26.800     Document Type: Article

References (25)

1. Buzdar AU, Hortobagyi GN. Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J. Clin. Oncol. 1998;16:348-353.
2. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 1998;50:151-196.
3. Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N, Boyle P. Tamoxifen for breast cancer among hysterectomised women. Lancet 2002;359:1122-1124.
4. Katzenellenbogen BS, Frasor J. Therapeutic targeting in the estrogen receptor hormonal pathway. Semin. Oncol. 2004;31 (Suppl 3):28-38.
5. Riggs BL, Hartman LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N. Engl. J. Med. 2003;348:618-629.
6. Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 2004;5:207-213.
7. Fabian CJ, Kimler BF. Selective estrogen-receptor modulators for primary prevention of breast cancer. J. Clin. Oncol. 2005;23:1644-1655.
8. Croxtall JD, Emmas C, White JO, Choudhary Q, Flower RJ. Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells. Biochem. Pharmacol. 1994;47:197-202.
9. Sugimoto Y, Tsukahara S, Imai Y, Ueda K, Tsuruo T. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol. Cancer Ther. 2003;2:105-112.
10. Samuels BL, Hollis DR, Rosner GL, Trump DL, Shapiro CL, Vogelzang NJ, Schilsky RL. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. Clin. Cancer Res. 1997;3:1977-1984.
11. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, Fine RL. High-dose oral tamoxifen, a potential multidrug-resistance- reversal agent: phase I trial in combination with vinblastine. J. Natl. Cancer Inst. 1992;84:1811-1816.
12. Smith DC, Trump DL. A phase I trial of high-dose oral tamoxifen and CHOPE. Cancer Chemother. Pharmacol. 1995;36:65-68.
13. Lindner DJ, Borden EC. Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis. Int. J. Cancer 1997;71:456-461.
14. Lindner DJ, Borden EC. Synergistic antitumor effects of a combination of Interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro. J. Interferon Cytokine Res. 1997;17:681-693.
15. Lindner DJ, Kolla V, Kalvakolanu DV. Borden EC. Tamoxifen enhances interferon-regulated gene expression in breast cancer cells. Mol. Cell. Biochem. 1997;167:169-177.
16. Borden E. Interferons. In: Holland J, Frei T, Kufe D, Pollock R, Weichselbaum R, Bast R, Gansler T, eds. Cancer Medicine, 6th ed. Baltimore: Williams & Wilkins; 2003:830-841.
17. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu. Rev. Biochem. 1998;67:227-264.
18. Vaughan PS, van Wijnen AJ, Stein JL, Stein GS. Interferon regulatory factors: growth control and histone gene regulation-it's not just interferon anymore. J. Mol. Med. 1997;75:348-359.
19. Berman E, McBride M, Lin S, Menedez-Botet C, Tong W. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia. Leukemia 1995;9:1631-1637.
20. Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004;100:612-620.
21. Hamilton M, Dahut W, Brawley O, Davis P, Wells-Jones T, Kohler D, Duray P, Liewehr DJ, Lakhani N, Steinberg SM, Figg WD, Reed E. A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancer. Acta Oncol 2003;42:195-201.
22. D'Cunha J, Ramanujam S, Wagner RJ, Witt PL, Knight E Jr, Borden EC. In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J. Immunol. 1996;157:4100-4108.
23. Witt PL, Storer BE, Bryan GT, Brown RR, Flashner M, Larocca AT, Colby CB, Borden EC. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta. J. Immunother. 1993;13:191-200.
24. Merritt JA, Ball LA, Sielaff KM, Meltzer DM, Borden EC. Modulation of 2′,5′-oligoadenylate synthetase in patients treated with alpha-interferon: effects of dose, schedule, and route of administration. J. Interferon Res. 1986;6:189-198.
25. Schiller JH, Storer B, Paulnock DM, Brown RR, Datta SP, Witt PL, Borden EC. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans. J. Clin. Invest. 1990;86:1211-1221.